Continuous Dopaminergic Stimulation in Parkinson's Disease – What Have We Learned from Positron-emission Tomography?

David J Brooks[1] and Nicola Pavese[2]

1. Hartnett Professor of Neurology, and Head, Centre for Neuroscience, Department of Medicine, Imperial College London;
2. Senior Investigator Scientist, Medical Research Council – Neurology PET Group, and Honorary Senior Lecturer, Imperial College London

Abstract

The hypothesis that pulsatile stimulation of striatal dopamine receptors in Parkinson's disease (PD) induces molecular and physiological changes in basal ganglia neurons and may contribute to the development of motor complications has led to the design of therapeutic strategies that provide more continuous dopaminergic stimulation. Newer agents and drug-delivery systems, such as slow-release preparations, catechol-O-methyltransferase and monoamine oxidase inhibitor agents, apomorphine and Duodopa™ infusions, represent a significant step towards less pulsatile dopaminergic administration. However, their efficacy in providing steady brain levels of dopaminergic stimulation in the short and longer term has not yet been proved in patients. This article briefly reviews and discusses the findings of published positron-emission tomography (PET) studies that support or oppose the value of continuous dopaminergic stimulation in PD. The potential future value of PET for proof of mechanism in this area is also debated.

Oral levodopa remains the most effective symptomatic drug for Parkinson's disease (PD); however, its long-term use is limited by the emergence of motor fluctuations and involuntary movements, particularly in young-onset patients. A growing number of pre-clinical and clinical studies suggest that non-physiological pulsatile stimulation of striatal dopamine (DA) receptors induced by the use of short-acting oral levodopa preparations, which produce swinging levels of synaptic DA, may contribute to the onset of motor fluctuations and dyskinesias. By contrast, more continuous and less pulsatile forms of dopaminergic stimulation delivered by longer-acting oral DA agonists result in a more stable clinical response and delay the development of motor complications, while steady infusions of apomorphine and levodopa can abolish motor fluctuations and dyskinesias.[1–3] Based on these observations, new levodopa formulations and alternative routes of administration for both levodopa and DA agonists have been introduced in the treatment of PD during the last decade, including slow-release preparations, addition of a catechol-O-methyltransferase (COMT) (entacapone or tolcapone) or monoamine oxidase B (MAOB) inhibitor (rasagaline), intravenous and enteral (duodenal) infusions of levodopa and transdermal administration and subcutaneous infusion of DA-receptor agonists. All of these strategies aim to optimise the clinical response by achieving stable and prolonged levels of synaptic DA. However, whether these strategies truly provide continuous dopaminergic stimulation has not yet been ascertained.

Positron-emission tomography (PET) is a neuroimaging technique that tags short-lived positron-emitting radioisotopes to chemical compounds of biological interest to produce 3D images of functional processes and drug-receptor occupancy in the body. In patients with PD, PET has been extensively used to investigate the function of brain dopaminergic nerve terminals, providing useful information on the density of functioning nerve terminals in the striatum and DA storage capacity, the availability of post-synaptic dopaminergic receptors and changes in synaptic DA levels following behavioural and pharmacological challenges. This article will briefly review and discuss the findings of published PET studies that support or oppose the value of continuous dopaminergic stimulation in PD.

Dopamine-replacement Treatment and Pre-synaptic Dopaminergic Function

The COMT inhibitors entacapone and tolcapone increase levodopa bioavailability in the plasma and increase its transport into the brain by blocking the peripheral 3-O-methylation of levodopa. Like levodopa, 3-O-methyldopa (3-OMD) is transported into the brain by the large neutral aminoacid (LNAA) carrier, but it is not decarboxylated. The effect of COMT inhibitors on striatal levodopa kinetics has been extensively investigated with ^{18}F-dopamine PET in both PD patients and healthy controls.[4–8] Striatal ^{18}F-dopa uptake, as measured by the influx constant K_i, reflects four sequential processes: transport by LNAA through the blood–brain barrier, uptake into dopaminergic neurons, metabolism to ^{18}F-dopamine by aromatic amino acid decarboxylase (AADC) and vesicular storage of ^{18}F-dopamine (see *Figure 1*). As ^{18}F-dopa and non-fluorinated levodopa follow the same metabolic pathway, peripheral COMT inhibition boosts ^{18}F-dopa bioavailability to the brain and increases its striatal uptake and subsequent metabolism in PD patients.

Several PET studies have been performed to measure the effect of peripheral COMT inhibitor entacapone on striatal uptake of ^{18}F-dopa.[4–7] Striatal K_i values can be computed by graphical analysis in two main ways. If a plasma input reference function is used, corrected for levels of ^{18}F-3-OMD, the striatal K_i value primarily reflects the rate constant for dopa decarboxylation. Alternatively, if an occipital cortex reference input function is used, the ^{18}F reference signal reflects occipital levels of both ^{18}F-dopa and ^{18}F-3-OMD in equilibrium with plasma. The striatal K_i then reflects the product of the rate constant for dopa decarboxylation and the striatal volume of distribution (VD) of ^{18}F-dopa.

Sawle and colleagues[4] performed ^{18}F-dopa PET in four early parkinsonian patients and six age-matched normal controls both before and after taking entacapone 400mg. Using a plasma input function, they found no change in striatal K_i after entacapone, implying that this agent does not influence dopa decarboxylation. However, they found a 45% increase in the striatal ^{18}F-dopa influx constant K_i after entacapone when computed with an occipital reference input function. As the effect of entacapone was to increase the fraction of unmetabolised ^{18}F-dopa in plasma from 22 to 56% 90 minutes after injection, this 45% increase in K_i represents a corresponding increase in striatal ^{18}F-dopa VD.

In a similar study in PD patients,[5] entacapone enhanced the striatal ^{18}F-dopa Ki (computed with an occipital reference input function) by 53.5% compared with placebo. However, changes in striatal ^{18}F-dopa uptake induced by entacapone are smaller in patients with advanced PD. This probably reflects a more severe loss of dopaminergic terminals, leading to impaired DA storage capacity in these patients.[6,7] From these studies it can be concluded that entacapone has little effect on ^{18}F-dopa decarboxylation in the striatum and that its main pharmacological effect is related to reduced peripheral 3-O-methylation and increased availability of plasma ^{18}F-dopa to the brain.

Unlike entacapone, which is purely a peripheral COMT inhibitor, tolcapone is a mixed peripheral and central COMT inhibitor.[9,10] The effect of tolcapone on COMT activity has been investigated in 12 PD patients with ^{18}F-dopa PET.[8] The study design comprised two PET scans on two separate days. Each patient received levodopa/carbidopa (100/125mg) with either tolcapone (200mg) or placebo one hour before an ^{18}F-dopa injection and was scanned for 240 minutes after tracer injection. ^{18}F-dopa K_i values were computed using a graphical approach with a plasma input function corrected for the presence of ^{18}F-3-OMD. Mean putaminal ^{18}F-dopa K_i values for the first 30–90 minutes, reflecting central AADC activity, were not modified by tolcapone pretreatment in PD. Mean putamen K_i values calculated 180–240 minutes after tracer injection, which reflect dopa metabolism by both central AADC and COMT, fell with placebo but were unchanged with tolcapone, implying that this agent was successfully blocking central COMT.

Effect of Dopamine-replacement Treatment on Post-synaptic Dopamine Function

[11]C-raclopride, a reversibly binding DA D_2/D_3 receptor ligand, is often used to assess post-synaptic dopaminergic receptor availability with PET. Its uptake is influenced by the synaptic level of DA, which competes for the same receptors, so ^{11}C-raclopride PET can potentially be used to monitor dopaminergic transmission.[11]

Studies in untreated PD patients have reported 10–20% increases in putaminal ^{11}C-raclopride binding, suggesting increased DA D_2 receptor availability is present.[12–14] This increase could simply reflect lower synaptic DA levels competing for DA D_2 sites or, conversely, could represent compensatory receptor upregulation to loss of nigrostriatal input. In PD patients treated long-term with levodopa, putaminal ^{11}C-raclopride binding returns to the normal range as synaptic DA levels are restored and adaptive upregulation reverses.[14–18]

Uitti et al.[19] scanned 10 untreated PD patients with ^{11}C-raclopride PET who were subsequently treated with either Sinemet® (300mg of levodopa daily) or Sinemet® CR (400mg of levodopa controlled-release daily) for six months and then crossed over to the other levodopa preparation for a further six months. At baseline, these workers found striatal ^{11}C-raclopride binding to be increased in the untreated PD patients. When the patients were re-scanned after six months of levodopa treatment, there were no significant differences in striatal ^{11}C-raclopride binding in either group from baseline. After the second six-month period of levodopa treatment, again no differences in ^{11}C-raclopride binding were seen compared with baseline or between type of levodopa preparation. Clinically, both groups received similar symptomatic benefit following treatment, and none developed motor fluctuations. These workers concluded that striatal DA D_2 normalisation via downregulation in PD following levodopa exposure must take longer than 12 months.

Striatal DA D_1 receptor availability can be assessed with ^{11}C-SCH23390 PET and is preserved in untreated PD patients, but reduced by 20% in patients chronically exposed to levodopa.[14,20]

To summarise, exposure to oral levodopa appears to have only mild effects on the total availability of DA D_1 and D_2 receptors in PD patients. Having said that, current PET studies with antagonist tracers are unable to separate signal from high and low agonist affinity-receptor conformations and it is possible that the relative sub-populations are altered. Additionally, they do not exclude that downstream neurotransmitter changes can be induced depending on the kinetics of DA-receptor stimulation.

Figure 2: Schematic Representation of the ^{11}C-raclopride Displacement Paradigm

Changes in ^{11}C-raclopride binding between baseline and post-treatment states (in this case administration of oral levodopa/carbidopa) represent a change in synaptic dopamine levels, reflecting the release of dopamine induced by levodopa administration.

Figure 3: ^{11}C-raclopride Positron-emission Tomography Images from a Parkinson's Disease Patient

Images taken at baseline and after oral administration of standard levodopa/carbidopa (250/25).

Effect of Dopamine-replacement Treatment on Striatal Dopamine Release

^{11}C-raclopride PET can also be used to assess fluctuations in synaptic concentrations of DA following pharmacological or behavioural challenges (see *Figure 2*). Rises in synaptic DA levels translate into decreases in DA D_2-receptor availability, which can be detected as reductions in ^{11}C-raclopride binding.[11] It has been estimated that a 10% reduction in ^{11}C-raclopride binding reflects a five-fold increase in synaptic DA levels.[21] This paradigm has recently been employed to assess the changes in synaptic DA levels after administration of a single dose of exogenous levodopa in PD patients (see *Figure 3*). Results from these studies have shown that striatal reductions in ^{11}C-raclopride binding after a levodopa challenge become greater as motor disability increases and the disease progresses.[22–25] Changes in ^{11}C-raclopride binding after oral administration of standard levodopa/carbidopa (250/25) were assessed in a group of PD patients

with and without peak-dose dyskinesias.[24] Each patient received three ^{11}C-raclopride PET scans. The first one was performed at baseline with the patient 'off' medication and the others at one hour and four hours after levodopa. PD patients with dyskinesias had larger increases in synaptic DA levels than patients with stable response to levodopa one hour after administration, whereas there were no between-group differences at four hours. This finding suggests that peak-dose dyskinesias are associated with enhanced pulses of DA release induced by levodopa administration. In line with this interpretation, our group has recently reported that large putaminal ^{11}C-raclopride binding changes induced by Sinemet® 275 were directly associated with higher dyskinesias scores during the scan session.[25]

The increased synaptic DA levels that result from levodopa administration in dyskinetic and in more advanced PD patients probably reflect the reduced DA storage capacity of the severely affected putamen. However, another explanation could be the reduction of DA transporters (DAT) available to clear the transmitter. In line with this theory, Sossi and colleagues[26] found a significant negative correlation between changes in synaptic DA concentration and binding of the DAT marker ^{11}C-methylphenidate. Greater reductions in ^{11}C-raclopride, indicative of lower changes in synaptic DA concentration and lower DA turnover, were observed to be associated with lower ^{11}C-methylphenidate binding. This finding suggests that DAT may play an important functional role in maintaining synaptic DA levels when pulsatile levodopa is administered. Therefore, decreases in DAT availability/function may result in greater oscillations in synaptic DA levels, contributing to the development of motor complications as the disease progresses.

Although previous studies indicate that ^{11}C-raclopride PET represents an useful tool to investigate turnover of levodopa-induced synaptic DA in PD, this paradigm has not been applied to assess the efficacy of approaches to continuous levodopa delivery. Our group is currently testing the hypothesis that enteral (duodenal) infusions of levodopa

provide stable and more prolonged synaptic levels of striatal DA compared with standard levodopa administration along with a sustained motor response.

Discussion

To our knowledge, there are no PET studies that have directly tested whether currently available drug approaches, which provide more sustained levodopa delivery, also provide stable and more prolonged synaptic levels of striatal DA along with a sustained motor response. However, it is clear that PET has a great potential in this specific research field and could provide valuable insight on the pharmacokinetics and pharmacodynamics of new agents and therapeutic strategies in PD. First, the entacapone and tolcapone experience clearly indicates that quantitative ^{18}F-dopa PET may be useful in assessing pharmacological manipulations of levadopa delivery into the brain. Late imaging can be informative if central COMT inhibition needs to be demonstrated. More importantly, sequential ^{11}C-raclopride PET scans can be used to compare the effects of intermittent and continuous dopaminergic delivery directly on striatal DA levels in PD patients. The same paradigm may also be useful to examine whether pulsatile and continuous dopaminergic stimulation have different long-term effects on pre-synaptic function and on the ability of the striatum to release DA in the synaptic cleft following an acute levodopa challenge. ■

David J Brooks is the Hartnett Professor of Neurology and Head of the Centre for Neuroscience in the Department of Medicine at Imperial College London. He is also a Senior Neurologist in Medical Diagnostics at GE Healthcare PLC. His research involves the use of positron-emission tomography and magnetic resonance imaging to diagnose and study the progression of Alzheimer's and Parkinson's disease and their validation of biomarker therapeutic trials. To date, he has published over 300 reports in peer-reviewed journals, including *Nature*. Professor Brooks' research is supported by grants from the UK Medical Research Council, the Alzheimer's Research Trust, the UK Parkinson's Disease Society, the Michael J Fox Foundation and industry. He has been an active member of the research advisory panels and boards for many of the leading Parkinson's disease and neurology societies and is on the Editorial Boards of *Brain*, the *Journal of Neural Transmission*, *Synapse, Molecular Imaging and Biology*, *Neurotherapeutics* and *Current Trends in Neurology*. He is a Fellow of the UK's Academy of Medical Science and has been the invited keynote speaker at several prestigious international scientific meetings.

Nicola Pavese is a Senior Investigator Scientist based at the Medical Research Council – Neurology PET Group in London and an Honorary Senior Lecturer at Imperial College London. His research activity has focused on the neuropharmacology and neurochemistry of movement disorders and he is investigating pathogenetic mechanisms underlying non-motor symptoms of Parkinson's disease by using functional imaging techniques.

1. Nutt JG, Obeso JA, Stocchi F, Continuous dopamine-receptor stimulation in advanced Parkinson's disease, *Trends Neurosci*, 2000;23(Suppl. 10):S109–15.
2. Stocchi F, Olanow CW, Continuous dopaminergic stimulation in early and advanced Parkinson's disease, *Neurology*, 2004;62(1 Suppl. 1):S56-63.
3. Olanow CW, Obeso JA, Stocchi F, Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications, *Lancet Neurol*, 2006; 5:677–87.
4. Sawle GV, Burn DJ, Morrish PK, et al., The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease, *Neurology*, 1994;44:1292–7.
5. Ishikawa T, Dhawan V, Chaly T, et al., Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis, *J Cereb Blood Flow Metab*, 1996;16:854–63.
6. Ruottinen HM, Rinne JO, Ruotsalainen UH, et al., Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease, *J Neural Transm Park Dis Dement Sect*, 1995;10:91–106.
7. Ruottinen HM, Rinne JO, Oikonen VJ, et al., Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction, *Synapse*, 1997;27:336–46.
8. Ceravolo R, Piccini P, Bailey DL, et al., 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease, *Synapse*, 2002;43(3):201–7.
9. Zurcher G, Dingemanse J, Da Prada M, Potent COMT inhibition by Ro 40-7592 in the periphery ad in the brain, *Adv Neurol*, 1993;60:641–647.

10. Duodet DJ, Chan GL, Holden JE, et al., Effects of monoamineoxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA, *Eur J Pharmacol*, 1997;334:31–8.
11. Laruelle M, Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review, *J Cereb Blood Flow Metab*, 2000;20:423–51.
12. Rinne JO, Laihinen A, Rinne UK, et al., PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease, *Mov Disord*, 1993;8:134–8.
13. Sawle GV, Playford ED, Brooks DJ, et al., Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications of the D2 receptor status, *Brain*, 1993;116:853–67.
14. Turjanski N, Lees AJ, Brooks DJ, In vivo studies on striatal dopamine D1 and D2 site binding in dopa-treated Parkinson's disease patients with and without dyskinesias, *Neurology*, 1997;49:717–23.
15. Shinotoh H, Hirayama K, Tateno Y, Dopamine D1 and D2 receptors in Parkinson's disease and striatonigral degeneration determined by PET, *Adv Neurol*, 1993;60: 488–93.
16. Antonini A, Vontobel P, Psylla M, et al., Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease, *Arch Neurol*, 1995;52:1183–90.
17. Antonini A, Schwarz J, Oertel WH, et al., Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride, *Mov Disord*, 1997;12:33–8.
18. Dentresangle C, Veyre L, Le Bars D, et al., Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]Dopa and [11C]-raclopride PET study, *Mov Disord*,

1999,14:1025–30.
19. Uitti RJ, Vingerhoets FJ, Hayward M, et al., Positron emission tomography (PET) measurements of striatal D(2) receptors in untreated Parkinson's disease patients with follow-up after 6 and 12 months' treatment with SINEMET® or SINEMET® CR, *Parkinsonism Relat Disord*, 1997;3:43–6.
20. Shinotoh H, Inoue O, Hirayama K, et al., Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study, *J Neurol Neurosurg Psychiatry*, 1993;56:467–72.
21. Breier A, Sur TP, Saunders R, et al., Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations, *Proc Natl Acad Sci*, 1997;94: 2569–74.
22. Tedroff J, Pedersen M, Aquilonius SM, et al., Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET, *Neurology*, 1996;46:1430–36.
23. de la Fuente-Fernandez R, Lu JQ, Sossi V, et al., Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover, *Ann Neurol*, 2001;49:298–303.
24. de la Fuente-Fernandez R, Sossi V, Huang Z, et al., Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias, *Brain*, 2004;127:2747–54.
25. Pavese N, Evans AH, Tai YF, et al., Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study, *Neurology*, 2006:14;67(9):1612–17.
26. Sossi V, de la Fuente-Fernández R, Schulzer M, et al., Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study, *Ann Neurol*, 2007;62:468–74.